Mineralocorticoid receptors in the heart: Lessons from cell-selective transgenic animals

Journal of Endocrinology

Volumn 224, Issue 1, 2015, Pages R1-R13

  Young, Morag J ^a,b   Rickard, Amanda J ^a,b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Aldosterone; Cardiovascular; Glucocorticoid; Knockout; Mineralocorticoid receptor

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EPLERENONE; MINERALOCORTICOID RECEPTOR; RENIN INHIBITOR; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CARDITIS; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE FIBROSIS; HUMAN; INFLAMMATORY CELL; MACROPHAGE; METABOLIC DISORDER; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSGENIC ANIMAL; TREATMENT OUTCOME; ANIMAL; CARDIOVASCULAR DISEASES; GENETICS; HEART; HEART MUSCLE; KNOCKOUT MOUSE; METABOLISM; MOUSE; PHYSIOLOGY;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CARDIOVASCULAR DISEASES; HEART; HUMANS; MICE; MICE, KNOCKOUT; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIUM; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84919624163     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-14-0471     Document Type: Review

References (93)

1. Amador CA, Barrientos V, Pena J, Herrada AA, Gonzalez M, Valdes S, Carrasco L, Alzamora R, Figueroa F, Kalergis AM et al. 2014 Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension 63 797-803. (doi:10.1161/HYPERTENSIONAHA. 113.02883).
2. Armanini D, Strasser T & Weber PC 1985 Characterization of aldosterone binding sites in circulating human mononuclear leukocytes. American Journal of Physiology 248 E388-E390.
3. Barbato JC, Rashid S, Mulrow PJ, Shapiro JI & Franco-Saenz R 2004 Mechanisms for aldosterone and spironolactone-induced positive inotropic actions in the rat heart. Hypertension 44 751-757. (doi:10.1161/01.HYP.0000144466.11568.7e).
4. Bienvenu LA, Morgan J, Rickard AJ, Tesch GH, Cranston GA, Fletcher EK, Delbridge LM & Young MJ 2012 Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology 153 3416-3425. (doi:10.1210/en.2011-2098).
5. Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, London GM & Safar ME 1997 Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. American Journal of Hypertension 10 1326-1334. (doi:10.1016/S0895-7061(97)00301-4).
6. Bodary PF, Sambaziotis C, Wickenheiser KJ, Rajagopalan S, Pitt B & Eitzman DT 2006 Aldosterone promotes thrombosis formation after arterial injury in mice. Arteriosclerosis, Thrombosis, and Vascular Biology 26 233. (doi:10.1161/01.ATV.0000195782.07637.44).
7. Bravo EL, Tarazi RC & Dustan HP 1977 Multifactorial analysis of chronic hypertension induced by electrolyte-active steroids in trained, unanesthetized dogs. Circulation Research 40 I140-I145.
8. Brilla CG & Weber KT 1992 Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. Journal of Laboratory and Clinical Medicine 120 893-901.
9. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G,Mendelsohn ME & Jaffe IZ 2008 Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circulation Research 102 1359-1367. (doi:10.1161/CIRCRESAHA.108.174235).
10. Chantong B, Kratschmar DV, Nashev LG, Balazs Z & Odermatt A 2012 Mineralocorticoid and glucocorticoid receptors differentially regulate NF-κB activity and pro-inflammatory cytokine production in murine BV-2 microglial cells. Journal of Neuroinflammation 9 260. (doi:10.1186/ 1742-2094-9-260).
11. Christ M, Wehling M, Kirsch E, Viengchareun S, Zennaro MC & Lombes M 2005 Enhancement of b-adrenergic cAMP-signaling by the mineralocorticoid receptor. Molecular and Cellular Endocrinology 231 23-31. (doi:10.1016/j.mce.2004.12.004).
12. Crabbe J 1963 Site of action of aldosterone on the bladder of the toad. Nature 200 787-788. (doi:10.1038/200787a0).
13. Dorrance AM, Osborn HL, Grekin R & Webb RC 2001 Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 281 R944-R950.
14. Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D & Cohn JN 1998 Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. European Heart Journal 19 1371-1376. (doi:10.1053/euhj.1998.1099).
15. Ehsan A, McGraw AP, Aronovitz MJ, Galayda C, Conte MS, Karas RH & Jaffe IZ 2013 Mineralocorticoid receptor antagonism inhibits vein graft remodeling in mice. Journal of Thoracic and Cardiovascular Surgery 145 1642-1649, 1649 e1641. (doi:10.1016/j.jtcvs.2012.08.007).
16. Endemann DH & Schiffrin EL 2004 Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus. Current Hypertension Reports 6 85-89. (doi:10.1007/s11906-004-0081-x).
17. Favre J, Gao J, Zhang AD, Remy-Jouet I, Ouvrard-Pascaud A, Dautreaux B, Escoubet B, Thuillez C, Jaisser F & Richard V 2011 Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. American Journal of Physiology. Heart and Circulatory Physiology 300 H2035-H2043. (doi:10.1152/ajpheart.00552.2010).
18. Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, Shagdarsuren E, Breu V, Haller H & Luft FC 2001 Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 37 787-793. (doi:10.1161/01.HYP.37.2.787).
19. Fishman AP 1982 Endothelium: a distributed organ of diverse capabilities. Annals of the New York Academy of Sciences 401 1-8. (doi:10.1111/ j.1749-6632.1982.tb25702.x).
20. Fraccarollo D, Galuppo P, Schraut S, Kneitz S, van Rooijen N, Ertl G & Bauersachs J 2008 Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension 51 905-914. (doi:10.1161/HYPERTENSIONAHA. 107.100941).
21. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schutz G, Frantz S, Ertl G & Bauersachs J 2011 Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123 400-408. (doi:10.1161/CIRCULATIONAHA. 110.983023).
22. Frieler RA, Ray JJ, Meng H, Ramnarayanan SP, Usher MG, Su EJ, Berger S, Pinsky DJ, Lawrence DA, Wang MM et al. 2012 Myeloid mineralocorticoid receptor during experimental ischemic stroke: effects of model and sex. Journal of the American Heart Association 1 e002584. (doi:10.1161/JAHA.112.002584).
23. Fujisawa G, Dilley R, Fullerton MJ & Funder JW 2001 Experimental cardiac fibrosis: differential time course of responses to mineralocorticoid-salt administration. Endocrinology 142 3625-3631. (doi:10.1210/ endo.142.8.8339).
24. Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S, Challande P, Jaffe IZ, Labat C, Lacolley P et al. 2014 Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension 63 520-526. (doi:10.1161/ HYPERTENSIONAHA.113.01967).
25. Gekle M, Freudinger R, Mildenberger S, Schenk K, Marschitz I & Schramek H 2001 Rapid activation of Na+/H+-Kexchange in MDCK cells by aldosterone involves MAP-kinase ERK1/2. Pflügers Archiv 441 781-786.
26. Goerdt S, Politz O, Schledzewski K, Birk R, Gratchev A, Guillot P, Hakiy N, Klemke CD, Dippel E, Kodelja V et al. 1999 Alternative versus classical activation of macrophages. Pathobiology 67 222-226. (doi:10.1159/ 000028096).
27. Gordon S 2003 Alternative activation of macrophages. Nature Reviews. Immunology 3 23-35. (doi:10.1038/nri978).
28. Gromotowicz A, Szemraj J, Stankiewicz A, Zakrzeska A, Mantur M, Jaroszewicz E, Rogowski F & Chabielska E 2011 Study of the mechanisms of aldosterone prothrombotic effect in rats. Journal of Renin-Angiotensin-Aldosterone System 12 430-439. (doi:10.1177/ 1470320310397405).
29. Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J & Feldman RD 2011 GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 57 442-451. (doi:10.1161/HYPERTENSIONAHA.110.161653).
30. Grossmann C, Benesic A, Krug AW, Freudinger R,Mildenberger S, Gassner B & Gekle M 2005 Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Molecular Endocrinology 19 1697-1710. (doi:10.1210/me.2004-0469).
31. Grossmann C, Husse B, Mildenberger S, Schreier B, Schuman K & Gekle M 2010 Colocalization of mineralocorticoid and EGF receptor at the plasma membrane. Biochimica et Biophysica Acta 1803 584-590. (doi:10.1016/j.bbamcr.2010.02.008).
32. Grundy HM, Simpson SA & Tait JF 1952 Isolation of a highly active mineralocorticoid from beef adrenal extract. Nature 169 795-796. (doi:10.1038/169795a0).
33. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C & Harrison DG 2007 Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. Journal of Experimental Medicine 204 2449-2460. (doi:10.1084/ jem.20070657).
34. Haseroth K, Gerdes D, Berger S, Feuring M, Gunther A, Herbst C, Christ M & Wehling M 1999 Rapid nongenomic effects of aldosterone in mineralocorticoid-receptor-knockout mice. Biochemical and Biophysical Research Communications 266 257-261. (doi:10.1006/bbrc.1999.1771).
35. Hashikabe Y, Suzuki K, Jojima T, Uchida K & Hattori Y 2006 Aldosterone impairs vascular endothelial cell function. Journal of Cardiovascular Pharmacology 47 609-613. (doi:10.1097/01.fjc.0000211738.63207.c3).
36. Herrada AA, Contreras FJ, Marini NP, Amador CA, Gonzalez PA, Cortes CM, Riedel CA, Carvajal CA, Figueroa F, Michea LF et al. 2010 Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. Journal of Immunology 184 191-202. (doi:10.4049/ jimmunol.0802886).
37. Iqbal J, Andrew R, Cruden NL, Kenyon CJ, Hughes KA, Newby DE, Hadoke PW & Walker BR 2014 Displacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist. Journal of Clinical Endocrinology and Metabolism 99 915-922.
38. Iwanami J, Mogi M, Okamoto S, Gao XY, Li JM, Min LJ, Ide A, Tsukuda K, Iwai M & Horiuchi M 2007 Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. European Journal of Pharmacology 566 153-159. (doi:10.1016/j.ejphar. 2007.03.043).
39. Jaffe IZ, Newfell BG, Aronovitz M, Mohammad NN, McGraw AP, Perreault RE, Carmeliet P, Ehsan A & Mendelsohn ME 2010 Placental growth factor mediates aldosterone-dependent vascular injury in mice. Journal of Clinical Investigation 120 3891-3900. (doi:10.1172/JCI40205).
40. Karst H, Berger S, Turiault M, Tronche F, Schutz G & Joels M 2005 Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. PNAS 102 19204-19207. (doi:10.1073/pnas.0507572102).
41. Kolla V & Litwack G 2000 Inhibition of mineralocorticoid-mediated transcription by NF-kappaB. Archives of Biochemistry and Biophysics 383 38-45. (doi:10.1006/abbi.2000.2045).
42. Lagrange J, Li Z, Fassot C, Bourhim M, Louis H, Nguyen Dinh Cat A, Parlakian A, Wahl D, Lacolley P, Jaisser F et al. 2014 Endothelial mineralocorticoid receptor activation enhances endothelial protein C receptor and decreases vascular thrombosis in mice. FASEB Journal 28 2062-2072. (doi:10.1096/fj.13-238188).
43. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE & Harrison DG 2003 Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. Journal of Clinical Investigation 111 1201-1209. (doi:10.1172/ JCI200314172).
44. Latouche C, El Moghrabi S, Messaoudi S, Nguyen Dinh Cat A, Hernandez-Diaz I, Alvarez de la Rosa D, Perret C, Lopez Andres N, Rossignol P, Zannad F et al. 2012 Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. Hypertension 59 966-972. (doi:10.1161/HYPERTENSIONAHA.111.187872).
45. Lim HY, Muller N, Herold MJ, van den Brandt J & Reichardt HM 2007 Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 122 47-53. (doi:10.1111/j.1365-2567.2007.02611.x).
46. Lother A, Berger S, Gilsbach R, Rosner S, Ecke A, Barreto F, Bauersachs J, Schutz G & Hein L 2011 Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 57 746-754. (doi:10.1161/HYPERTENSIONAHA.110.163287).
47. Lupher ML Jr & Gallatin WM 2006 Regulation of fibrosis by the immune system. Advances in Immunology 89 245-288.
48. Mann DL 2011 The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circulation Research 108 1133-1145. (doi:10.1161/CIRCRESAHA.110.226936).
49. Martinez FO, Sica A, Mantovani A & Locati M 2008 Macrophage activation and polarization. Frontiers in Bioscience 13 453-461. (doi:10.2741/2692).
50. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME et al. 2012 Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nature Medicine 18 1429-1433. (doi:10.1038/nm.2891).
51. McEneaney V, Harvey BJ & Thomas W 2008 Aldosterone regulates rapid trafficking of epithelial sodium channel subunits in renal cortical collecting duct cells via protein kinase D activation. Molecular Endocrinology 22 881-892. (doi:10.1210/me.2007-0225).
52. McEneaney V, Dooley R, Harvey BJ & Thomas W 2010 Protein kinase D stabilizes aldosterone-induced ERK1/2 MAP kinase activation in M1 renal cortical collecting duct cells to promote cell proliferation. Journal of Steroid Biochemistry and Molecular Biology 118 18-28. (doi:10.1016/j.jsbmb.2009.09.014).
53. McGraw AP, Bagley J, Chen WS, Galayda C, Nickerson H, Armani A,Caprio M, Carmeliet P & Jaffe IZ 2013 Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factordependent mechanism. Journal of the American Heart Association 2 e000018. (doi:10.1161/JAHA.112.000018).
54. Messaoudi S, Gravez B, Tarjus A, Pelloux V, Ouvrard-Pascaud A, Delcayre C, Samuel J, Launay JM, Sierra-Ramos C, Alvarez de la Rosa D et al. 2013 Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo. Hypertension 61 361-367. (doi:10.1161/HYPERTENSIONAHA. 112.198986).
55. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL et al. 2002 Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circulation Research 90 E58-E65. (doi:10.1161/01.RES.0000012569.55432.02).
56. Newfell BG, Iyer LK, Mohammad NN, McGraw AP, Ehsan A, Rosano G, Huang PL, Mendelsohn ME & Jaffe IZ 2011 Aldosterone regulates vascular gene transcription via oxidative stress-dependent and-independent pathways. Arteriosclerosis, Thrombosis, and Vascular Biology 31 1871-1880. (doi:10.1161/ATVBAHA.111.229070).
57. Oberleithner H 2005 Aldosterone makes human endothelium stiff and vulnerable. Kidney International 67 1680-1682. (doi:10.1111/j.1523-1755.2005.00263.x).
58. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, Nguyen Dinh Cat A, Royer A, Le Quang K, Charpentier F, Demolombe S et al. 2005 Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111 3025-3033. (doi:10.1161/CIRCULATIONAHA.104.503706).
59. Owens GK 1995 Regulation of differentiation of vascular smooth muscle cells. Physiological Reviews 75 487-517.
60. Owens GK, Kumar MS & Wamhoff BR 2004 Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiological Reviews 84 767-801. (doi:10.1152/physrev.00041.2003).
61. Oyamada N, Sone M, Miyashita K, Park K, Taura D, Inuzuka M, Sonoyama T, Tsujimoto H, Fukunaga Y, Tamura N et al. 2008 The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology 149 3764-3777. (doi:10.1210/en.2007-1770).
62. Park JB & Schiffrin EL 2001 Small artery remodeling is themost prevalent (earliest?) form of target organ damage inmild essential hypertension Journal of Hypertension 19 921-930. (doi:10.1097/00004872-200105000-00013).
63. Pearce PT & Funder JW 1988 Steroid binding to cardiac type I receptors: in vivo studies. Journal of Hypertension. Supplement: Official Journal of the International Society of Hypertension 6 S131-S133.
64. Pearce D & Yamamoto KR 1993 Mineralocorticoid and glucocorticoid receptor activities distinguished by nonreceptor factors at a composite response element. Science 259 1161-1165. (doi:10.1126/science.8382376).
65. Piera-Velazquez S, Li Z & Jimenez SA 2011 Role of endothelialmesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. American Journal of Pathology 179 1074-1080. (doi:10.1016/ j.ajpath.2011.06.001).
66. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J & Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine 341 709-717. (doi:10.1056/NEJM199909023411001).
67. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D et al. 2001 The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovascular Drugs and Therapy 15 79-87. (doi:10.1023/A:1011119003788).
68. Pober JS & Sessa WC 2007 Evolving functions of endothelial cells in inflammation. Nature Reviews. Immunology 7 803-815. (doi:10.1038/ nri2171).
69. Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi SA & Jaffe IZ 2014 Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arteriosclerosis, Thrombosis, and Vascular Biology 34 355-364. (doi:10.1161/ATVBAHA. 113.302854).
70. Rickard AJ & Young MJ 2009 Corticosteroid receptors, macrophages and cardiovascular disease. Journal of Molecular Endocrinology 42 449-459. (doi:10.1677/JME-08-0144).
71. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ & Young MJ 2009 Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54 537-543. (doi:10.1161/HYPERTENSIONAHA. 109.131110).
72. Rickard AJ, Morgan J, Bienvenu LA, Fletcher EK, Cranston GA, Shen JZ, Reichelt ME, Delbridge LM & Young MJ 2012 Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone/salt-mediated inflammation and cardiac fibrosis. Hypertension 60 1443-1450. (doi:10.1161/HYPERTENSIONAHA.112.203158).
73. Rickard AJ, Morgan J, Chrissobolis S, Miller AA, Sobey CG & Young MJ 2014 Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/ salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension 63 1033-1040. (doi:10.1161/HYPERTENSIONAHA. 113.01803).
74. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG & Delyani JA 2002 Aldosterone induces a vascular inflammatory phenotype in the rat heart. American Journal of Physiology. Heart and Circulatory Physiology 283 H1802-H1810.
75. Rossier MF, Lenglet S, Vetterli L, Python M & Maturana A 2008 Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricular cardiomyocytes. Hypertension 52 721-728. (doi:10.1161/HYPERTENSIONAHA.108.114223).
76. Rossier MF, Python M & Maturana AD 2010 Contribution of mineralocorticoid and glucocorticoid receptors to the chronotropic and hypertrophic actions of aldosterone in neonatal rat ventricular myocytes. Endocrinology 151 2777-2787. (doi:10.1210/en. 2009-1375).
77. Schafer A, Fraccarollo D, Hildemann S, Christ M, Eigenthaler M, Kobsar A, Walter U & Bauersachs J 2003 Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thrombosis and Haemostasis 89 1024-1030.
78. Schafer A, Vogt C, Fraccarollo D, Widder J, Flierl U, Hildemann SK, Ertl G & Bauersachs J 2010 Eplerenone improves vascular function and reduces platelet activation in diabetic rats. Journal of Physiology and Pharmacology 61 45-52.
79. Schafer N, Lohmann C, Winnik S, van Tits LJ, Miranda MX, Vergopoulos A, Ruschitzka F, Nussberger J, Berger S, Luscher TF et al. 2013 Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. European Heart Journal 34 3515-3524. (doi:10.1093/eurheartj/eht095).
80. Schiffrin EL 2014 Immune mechanisms in hypertension and vascular injury. Clinical Science 126 267-274. (doi:10.1042/CS20130407).
81. Selye H 1946 The general adaptation syndrome and the diseases of adaptation. Journal of Clinical Endocrinology and Metabolism 6 117-230. (doi:10.1210/jcem-6-2-117).
82. Shen JZ, Morgan J, Tesch GH, Fuller PJ & Young MJ 2014 CCL2-dependent macrophage recruitment is critical for mineralocorticoid receptormediated cardiac fibrosis, inflammation, and blood pressure responses in male mice. Endocrinology 155 1057-1066. (doi:10.1210/en.2013-1772).
83. Stankiewicz A, Gromotowicz A, Szemraj J, Wojewodzka-Zelezniakowicz M, Skrzypkowski P & Chabielska E 2007 Acute aldosterone infusion enhances thrombosis development in normotensive rats. Thrombosis and Haemostasis 98 697-699.
84. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J & Horiuchi M 2006 Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology 26 917-921.
85. Tanaka J, Fujita H, Matsuda S, Toku K, Sakanaka M & Maeda N 1997 Glucocorticoid-and mineralocorticoid receptors in microglial cells: the two receptors mediate differential effects of corticosteroids. Glia 20 23-37. (doi:10.1002/(SICI)1098-1136(199705)20:1<23::AID-GLIA3> 3.0.CO;2-6).
86. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schutz G, Lumeng CN & Mortensen RM 2010 Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. Journal of Clinical Investigation 120 3350-3364. (doi:10.1172/JCI41080).
87. Wehling M 1994 Nongenomic actions of steroid hormones. Trends in Endocrinology and Metabolism 5 347-353. (doi:10.1016/1043-2760(94)90165-1).
88. Wei Y,Whaley-Connell AT, Habibi J, Rehmer J, Rehmer N, Patel K,HaydenM, DeMarco V, Ferrario CM, Ibdah JA et al. 2009 Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension 53 158-165. (doi:10.1161/HYPERTENSIONAHA.108.121954).
89. Wright FS & Giebisch G 1978 Renal potassium transport: contributions of individual nephron segments and populations. American Journal of Physiology 235 F515-F527.
90. Wynn TA 2008 Cellular and molecular mechanisms of fibrosis. Journal of Pathology 214 199-210. (doi:10.1002/path.2277).
91. Yang J & Fuller PJ 2012 Interactions of the mineralocorticoid receptor-within and without. Molecular and Cellular Endocrinology 350 196-205. (doi:10.1016/j.mce.2011.07.001).
92. Young MJ, Moussa L, Dilley R & Funder JW 2003 Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11β-hydroxysteroid dehydrogenase inactivation. Endocrinology 144 1121-1125. (doi:10.1210/en.2002-220926).
93. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B & Group E-HS 2011 Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine 364 11-21. (doi:10.1056/ NEJMoa1009492).